BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/26/2019 9:05:11 AM | Browse: 729 | Download: 1069
 |
Received |
|
2018-09-21 01:40 |
|
Peer-Review Started |
|
2018-09-21 06:37 |
|
To Make the First Decision |
|
2018-10-25 02:06 |
|
Return for Revision |
|
2018-10-29 01:25 |
|
Revised |
|
2019-01-21 17:38 |
|
Second Decision |
|
2019-01-26 07:13 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-01-26 23:31 |
|
Articles in Press |
|
2019-01-26 23:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-02-26 02:22 |
|
Publish the Manuscript Online |
|
2019-02-26 09:05 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Minireviews |
| Article Title |
Immune checkpoint inhibitor-induced colitis: A comprehensive review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Aniruddh Som, Rohan Mandaliya, Dana Alsaadi, Maham Farshidpour, Aline Charabaty, Nidhi Malhotra and Mark C Mattar |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mark C Mattar, Department of Gastroenterology, MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, DC 20007, United States. mark.c.mattar@medstar.net |
| Key Words |
Immune checkpoint inhibitors; Immune-related adverse events; Cytotoxic T-lymphocyte-associated antigen 4; Programmed cell death protein 1; Programmed death-ligand 1; Immune-mediated colitis |
| Core Tip |
Immune-mediated colitis (IMC) is a common immune related adverse event associated with immune checkpoint inhibitors. It typically occurs 5–10 wk after the 2nd or 3rd dose of treatment. Endoscopically, it is indistinguishable from inflammatory bowel disease with significant overlap in histology. Optimal management of IMC requires early recognition and timely use of corticosteroids. About one third to two third of the patients are steroid refractory. Infliximab is the second line therapy in these patients. Recent reports have shown Vedolizumab being more gut specific efficacious in steroid and infliximab refractory cases. Fecal microbiota transplant has recently been reported to be successful in steroid refractory cases. |
| Publish Date |
2019-02-26 09:05 |
| Citation |
Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, Mattar MC. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases 2019; 7(4): 405-418 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i4/405.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i4.405 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
